Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane
Market Analysis and Insights: Global Sulfinpyrazone Market
Due to the COVID-19 pandemic, the global Sulfinpyrazone market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Capsule accounting for % of the Sulfinpyrazone global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Sulfinpyrazone market size is valued at US$ million in 2021, while the US and Europe Sulfinpyrazone are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Sulfinpyrazone landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Sulfinpyrazone include Medivis, Incepta, TTY Biopharm, AA Pharma, American Taiwan Biopharm (ATB), Norris Pharm, ARK Pharm, Biosynth and Hairui Chemical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Sulfinpyrazone Scope and Segment
Sulfinpyrazone market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Sulfinpyrazone market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Capsule
Tablet
Segment by Application
Hospital
Drug Store
By Company
Medivis
Incepta
TTY Biopharm
AA Pharma
American Taiwan Biopharm (ATB)
Norris Pharm
ARK Pharm
Biosynth
Hairui Chemical
BLD Pharm
CSNpharm
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE